Actively Recruiting
A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) With or Without JS004 or Docetaxel in Advanced NSCLC After Platinum-based Chemotherapy and Immunotherapy
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-02-06
66
Participants Needed
18
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and early effects of JS207 in adults with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving platinum-based chemotherapy and immunotherapy. This phase II trial aims to assess how well JS207 works alone or combined with other treatments in this setting. Participants receive one of three treatments: JS207 with docetaxel chemotherapy every three weeks, JS207 with JS004 antibody every three weeks, or JS207 alone at 10mg/kg or another dose. These groups allow comparison of different combinations to explore potential benefits and safety profiles. During the study, participants will be monitored for tumor response, disease control, duration of response, progression-free survival, overall survival, and any adverse effects or laboratory abnormalities. These outcomes will be assessed over periods ranging from 1.5 to 2 years to gather comprehensive information about treatment effects and safety.
CONDITIONS
Brief Title
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC), metastatic, or recurrent NSCLC not suitable for surgery or radical treatment
- Disease progression after PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel)
- At least one measurable lesion according to RECIST v1.1
You will not qualify if you...
- Presence of combined neuroendocrine component confirmed by pathology
- Known EGFR sensitivity mutation or ALK fusion
- Tumor involving important blood vessels or with necrosis/air spaces that may increase bleeding risk as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years depending on treatment response and tolerability
Participants receive JS207 with or without additional drugs as part of their treatment for advanced NSCLC.
Repeated visits every 3 weeks for drug administration and assessments
Duration - Up to 6 months after treatment completion
Participants are monitored for safety and efficacy outcomes after treatment ends.
Periodic visits for up to 6 months after treatment
Trial Site Locations
Total: 18 locations
1
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 101100
Actively Recruiting
2
Jilin Cancer Hospital
Jilin City, Changchun, China, 130012
Actively Recruiting
3
Hunan Cancer Hospital
Hunan, Changsha, China, 410031
Actively Recruiting
4
West China Hospital, Sichuan University
Sichuan, Chengdu, China, 610044
Actively Recruiting
5
Second Affiliated Hospital, PLA Academy of Military Medical Sciences
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
6
Army Medical Center, PLA
Chongqing, Chongqing Municipality, China, 400042
Actively Recruiting
7
The First Affiliated Hospital of Guangzhou Medical University
Guangdong, Guangzhou, China, 510120
Actively Recruiting
8
Harbin Medical University Cancer Hospital
Heilongjiang, Harbin, China, 150081
Actively Recruiting
9
Anyang Tumor Hospital
Anyang, Henan, China, 455000
Actively Recruiting
10
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 471003
Actively Recruiting
11
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453100
Actively Recruiting
12
The First People's Hospital of Changde
Changde, Hunan, China, 415003
Actively Recruiting
13
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, China, 330000
Actively Recruiting
14
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
15
The Third People's Hospital of Datong
Datong, Shanxi, China, 037008
Actively Recruiting
16
Yibin Second People's Hospital
Yibin, Sichuan, China, 644000
Actively Recruiting
17
Affiliated Tumor Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China, 830011
Actively Recruiting
18
Shanghai Pulmonary Hospital
Shanghai, China, 200433
Not Yet Recruiting
Research Team
X
Xiaojun Wang, Master
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here